Tag: DXCM

Dexcom, Inc. (Nasdaq: DXCM) reported disappointing third-quarter 2024 earnings on Thursday, revealing just 2% revenue growth year-over-year to $994.2 million. This slow revenue expansion—particularly driven by a 2% decline in U.S. revenue—comes as the stock continues to trade at an elevated 46 times earnings, raising concerns about its valuation given the lack of strong growth.… Read more